BioAgilytix, a provider of large molecule bioanalytical testing services, has acquired Cambridge Biomedical, a CRO specializing in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint into the Cambridge, MA biotech hub, and adds capacity with Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility and GxP labs in Durham, NC and Hamburg, Germany. The acquisition also adds seasoned bioanalytical scientists enhancing BioAgilytix’s expertise in biomarkers, immunogenicity, cell-based assays, and pharmacokinetics to support all phases of biologics development. Cambridge Biomedical has extensive capabilities in kit production as well as a molecular suite equipped with the latest generation of PCR platforms, both of which will be immediately available to BioAgilytix’s customers.
 
“We’re proud to have Cambridge Biomedical join BioAgilytix in our collective mission to serve customers’ evolving and expanding bioanalytical needs,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “Our companies have many synergies, both exclusively focused in large molecules and today supporting development of some of the most innovative and complex biologics, including cell and gene therapeutics. We also share the same commitment to quality and service, which has allowed both companies to build a strong scientific track record and impressive customer base. Together we will be able to offer the same premier scientific solutions and quality results, but on a larger scale. Our customers will now have access to additional scientific resources and platforms in the Cambridge area of Massachusetts, which is a hotbed of biotech innovation, and Cambridge Biomedical’s customers will be able to leverage BioAgilytix’s premier labs in the Research Triangle area of North Carolina and in Hamburg, Germany to seamlessly support large and global studies.”
 
“As we were considering the best way to enable Cambridge Biomedical to continue on its strong growth trajectory, it became clear that we wanted a partner – one as committed to upholding our high scientific standards and ‘people first’ values,” said Barbara Osband, Founder and Chief Executive Officer of Cambridge Biomedical. “Having personally spent more than 18 years building our business and creating a culture that recognizes being in the health care industry mandates a special level of competence, caring, and integrity, I was thrilled to merge with BioAgilytix whose value systems mirror our own. I couldn’t be more confident placing Cambridge Biomedical in the capable hands of BioAgilytix’s leadership team.”
 
Cambridge Biomedical was represented by Fairmount Partners throughout this transaction. Neal McCarthy, Managing Director of Fairmount, commented, “We are thrilled to have helped these two great groups of people to combine their world leading expertise in large molecules.”